Integrated Diagnostics, a Seattle, WA-based developer of leader in molecular diagnostics, has raised $10m in the third tranche of its Series A financing.
The company plans to use the funds to complete clinical development of its in vitro proteomic-based diagnostics programs and prepare for them for commercialization. The capital will also be used to advance its novel class of molecules – protein-catalyzed capture agents (PCCs) – for use in in vivo molecular imaging and therapeutics.
Integrated Diagnostics also said it appointed Donald “Guy” Seaton as CFO and James “Jim” Garner as CBO.
Founded in October 2009 and led by CEO Albert “Al” A. Luderer, Ph.D., the company, which is based on Dr. Lee Hood’s research in protein blood markers at The Institute for Systems Biology (ISB), is developing large-scale, blood-based molecular diagnostics that detect important diseases like lung cancer and Alzheimer’s at their earliest stages by simultaneously monitoring tens to hundreds of disease markers.
Investors in Integrated Diagnostics include InterWest Partners, The Wellcome Trust, and BioTechCube Luxembourg. Foundational intellectual property is exclusively licensed from the Institute of Systems Biology and Caltech.